Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma

Abstract

Background: Asthma affects up to nearly 40% of patients with allergic rhinitis (AR). Poor control of AR symptoms is associated with poor asthma control. The goal of this study was to evaluate the effect of AR treatment with MP-AzeFlu on symptoms of AR as well as symptoms of asthma. Methods: This prospective study used a visual analog scale (VAS) to assess symptoms of AR and asthma before and after treatment with MP-AzeFlu (Dymista ® ; azelastine hydrochloride plus fluticasone propionate; 1 spray in each nostril twice daily for 2 weeks). Participants suffered from moderate-to-severe AR according to Allergic Rhinitis and its Impact on Asthma criteria, with acute AR symptoms (AR-VAS scores ≥ 50 mm) on inclusion day. In addition to symptom assessment, patients recorded the impact of AR symptoms on quality-of-life measures before, during, and at the conclusion of the treatment period (approximately 14 days). Patients self-reported change in frequency of their usage of asthma reliever medication on the last day of treatment. Results: Of 1103 study participants, 267 (24.2%) had comorbid asthma. These participants reported using a mean of 5.1 puffs of asthma reliever medication in the week before treatment with MP-AzeFlu. A total of 81.8% of patients with comorbid asthma responded to AR therapy (AR-VAS < 50 mm on at least 1 study day). Among patients with AR and comorbid asthma, MP-AzeFlu was associated with improved VAS scores across all study parameters, including AR symptom severity, asthma symptom severity, sleep quality, daily work or school activities, daily social activities, and daily outdoor activities. Asthma symptom severity decreased from a mean of 48.9 mm to 24.1 mm on the VAS. Selfreported frequency of asthma reliever medication use was reduced for 57.6% of participants (n = 139/241). Conclusion: MP-AzeFlu used to relieve AR symptoms was associated with reduced asthma symptom VAS scores and frequency of asthma reliever medication usage. Changes in overall symptoms of AR and asthma were correlated.

An algorithm recommendation for the pharmacological management of allergic rhinitis in Ukraine: a consensus statement from an expert panel

“…Among patients with AR and comorbid asthma, MP-AzeFlu improved VAS scores across all study parameters, including AR symptoms, sleep quality, daily work or school activities, daily social activities, and daily outdoor activities. Asthma symptom severity improved by 24.8 mm on the VAS along with reduction in usage of asthma reliever medication [61].…”

“…In general, MP-AzeFlu was well-tolerated in clinical [52,62] and real-life studies [9,61], with no safety findings that would preclude its long-term use. Most of the adverse events (AEs) were mild-to-moderate in severity and unrelated to treatment.…”

Gambaran Riwayat Asma pada Pasien Rinitis Alergi di RSUP Dr. M. Djamil Padang

“…Dalam penelitian tersebut sebanyak 146 dari 267 orang (54,7%) yang memiliki rinitis alergi disertai asma berjenis kelamin perempuan. 24 Prevalensi rinitis alergi dan asma lebih banyak ditemukan pada laki-laki saat usia anak hingga mendekati masa pubertas. Namun, saat masa pubertas sekitar usia 10-18 tahun, prevalensi rinitis alergi dan asma ditemukan paling banyak pada perempuan.…”

Allergic Rhinitis Seasonality, Severity, and Disease Control Influence Anxiety and Depression

“…However, the literature is scarce and inconclusive regarding how seasonality and severity of AR may influence its association with mental illness 9,10 . In fact, although it has been shown that an effective control of AR is important for the prevention or reduction of some of its comorbidities (such as sleep disorders, allergic conjunctivitis, or asthma exacerbations), 11 the association between AR control in the frequency of anxiety and depression symptoms has not yet been fully described 12–14 …”